Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Cellular and Molecular Networking Within the Ecosystem of Cancer Cell Communication via Tunneling Nanotubes.

Lou E, Zhai E, Sarkari A, Desir S, Wong P, Iizuka Y, Yang J, Subramanian S, McCarthy J, Bazzaro M, Steer CJ.

Front Cell Dev Biol. 2018 Oct 2;6:95. doi: 10.3389/fcell.2018.00095. eCollection 2018.

2.

UNC-45A Is a Novel Microtubule-Associated Protein and Regulator of Paclitaxel Sensitivity in Ovarian Cancer Cells.

Mooneyham A, Iizuka Y, Yang Q, Coombes C, McClellan M, Shridhar V, Emmings E, Shetty M, Chen L, Ai T, Meints J, Lee MK, Gardner M, Bazzaro M.

Mol Cancer Res. 2018 Oct 15. doi: 10.1158/1541-7786.MCR-18-0670. [Epub ahead of print]

PMID:
30322860
3.

Corrigendum to "Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells" [Gyncol. Oncol. 144 (2017) 598-606].

Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK.

Gynecol Oncol. 2018 Oct;151(1):182-186. doi: 10.1016/j.ygyno.2018.07.015. Epub 2018 Aug 7. No abstract available.

4.

RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.

Hellweg R, Mooneyham A, Chang Z, Shetty M, Emmings E, Iizuka Y, Clark C, Starr T, Abrahante JH, Schütz F, Konecny G, Argenta P, Bazzaro M.

Horm Cancer. 2018 Oct;9(5):326-337. doi: 10.1007/s12672-018-0337-6. Epub 2018 Jun 27.

PMID:
29951943
5.

UNC-45A is required for neurite extension via controlling NMII activation.

Iizuka Y, Mooneyham A, Sieben A, Chen K, Maile M, Hellweg R, Schütz F, Teckle K, Starr T, Thayanithy V, Vogel RI, Lou E, Lee MK, Bazzaro M.

Mol Biol Cell. 2017 May 15;28(10):1337-1346. doi: 10.1091/mbc.E16-06-0381. Epub 2017 Mar 29.

6.

Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.

Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK.

Gynecol Oncol. 2017 Mar;144(3):598-606. doi: 10.1016/j.ygyno.2017.01.015. Epub 2017 Jan 19. Erratum in: Gynecol Oncol. 2018 Oct;151(1):182-186.

7.

Targeting Deubiquitinating Enzymes and Autophagy in Cancer.

Mooneyham A, Bazzaro M.

Methods Mol Biol. 2017;1513:49-59. Review.

PMID:
27807830
8.

USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment.

Vogel RI, Pulver T, Heilmann W, Mooneyham A, Mullany S, Zhao X, Shahi M, Richter J, Klein M, Chen L, Ding R, Konecny G, Kommoss S, Winterhoff B, Ghebre R, Bazzaro M.

Oncotarget. 2016 May 24;7(21):30962-76. doi: 10.18632/oncotarget.8821.

9.

UNC-45A Is a Nonmuscle Myosin IIA Chaperone Required for NK Cell Cytotoxicity via Control of Lytic Granule Secretion.

Iizuka Y, Cichocki F, Sieben A, Sforza F, Karim R, Coughlin K, Isaksson Vogel R, Gavioli R, McCullar V, Lenvik T, Lee M, Miller J, Bazzaro M.

J Immunol. 2015 Nov 15;195(10):4760-70. doi: 10.4049/jimmunol.1500979. Epub 2015 Oct 5.

10.

Method for measuring the activity of deubiquitinating enzymes in cell lines and tissue samples.

Griffin P, Sexton A, Macneill L, Iizuka Y, Lee MK, Bazzaro M.

J Vis Exp. 2015 May 10;(99):e52784. doi: 10.3791/52784.

11.

Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.

Vogel RI, Coughlin K, Scotti A, Iizuka Y, Anchoori R, Roden RB, Marastoni M, Bazzaro M.

Oncotarget. 2015 Feb 28;6(6):4159-70.

12.

Measurement of deubiquitinating enzyme activity via a suicidal HA-Ub-VS probe.

Rivard C, Bazzaro M.

Methods Mol Biol. 2015;1249:193-200. doi: 10.1007/978-1-4939-2013-6_14.

PMID:
25348307
13.

Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.

Coughlin K, Anchoori R, Iizuka Y, Meints J, MacNeill L, Vogel RI, Orlowski RZ, Lee MK, Roden RB, Bazzaro M.

Clin Cancer Res. 2014 Jun 15;20(12):3174-86. doi: 10.1158/1078-0432.CCR-13-2658. Epub 2014 Apr 11.

14.

Method for obtaining primary ovarian cancer cells from solid specimens.

Pribyl LJ, Coughlin KA, Sueblinvong T, Shields K, Iizuka Y, Downs LS, Ghebre RG, Bazzaro M.

J Vis Exp. 2014 Feb 4;(84):e51581. doi: 10.3791/51581.

15.

Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors.

Sueblinvong T, Ghebre R, Iizuka Y, Pambuccian SE, Isaksson Vogel R, Skubitz AP, Bazzaro M.

PLoS One. 2012;7(11):e50519. doi: 10.1371/journal.pone.0050519. Epub 2012 Nov 30.

16.

Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.

Anchoori RK, Khan SR, Sueblinvong T, Felthauser A, Iizuka Y, Gavioli R, Destro F, Isaksson Vogel R, Peng S, Roden RB, Bazzaro M.

PLoS One. 2011;6(8):e23888. doi: 10.1371/journal.pone.0023888. Epub 2011 Aug 31.

17.

α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.

Bazzaro M, Anchoori RK, Mudiam MK, Issaenko O, Kumar S, Karanam B, Lin Z, Isaksson Vogel R, Gavioli R, Destro F, Ferretti V, Roden RB, Khan SR.

J Med Chem. 2011 Jan 27;54(2):449-56. doi: 10.1021/jm100589p. Epub 2010 Dec 27.

18.

Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment.

Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, Roden RB.

Clin Cancer Res. 2009 Jan 15;15(2):570-7. doi: 10.1158/1078-0432.CCR-08-1813.

19.

Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.

Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB.

Clin Cancer Res. 2008 Nov 15;14(22):7340-7. doi: 10.1158/1078-0432.CCR-08-0642.

20.

Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility.

Bazzaro M, Santillan A, Lin Z, Tang T, Lee MK, Bristow RE, Shih IeM, Roden RB.

Am J Pathol. 2007 Nov;171(5):1640-9. Epub 2007 Sep 14.

21.

Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.

Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih IeM, Roden RB.

Cancer Res. 2006 Apr 1;66(7):3754-63.

22.

Synthesis and activity of N-benzyl pseudopeptides HIV protease inhibitors.

Marastoni M, Bazzaro M, Bortolotti F, Tomatis R.

Bioorg Med Chem. 2003 May 29;11(11):2477-83.

PMID:
12735995
23.

Cytotoxic T lymphocyte epitope analogues containing cis- or trans-4-aminocyclohexanecarboxylic acid residues.

Marastoni M, Bazzaro M, Micheletti F, Gavioli R, Tomatis R.

Bioorg Med Chem. 2002 Sep;10(9):3061-6.

PMID:
12110330
24.

Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.

Micheletti F, Monini P, Fortini C, Rimessi P, Bazzaro M, Andreoni M, Giuliani M, Traniello S, Ensoli B, Gavioli R.

Immunology. 2002 Jul;106(3):395-403.

25.

Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals.

Vertuani S, Bazzaro M, Gualandi G, Micheletti F, Marastoni M, Fortini C, Canella A, Marino M, Tomatis R, Traniello S, Gavioli R.

Eur J Immunol. 2002 Jan;32(1):144-54.

26.

Peptide analogues of a subdominant epitope expressed in ebv-associated tumors: synthesis and immunological activity.

Marastoni M, Bazzaro M, Micheletti F, Gavioli R, Tomatis R.

J Med Chem. 2001 Jul 5;44(14):2370-3.

PMID:
11428932
27.

HIV-1 protease inhibitors containing an N-hydroxyamino acid core structure.

Marastoni M, Bazzaro M, Salvadori S, Bortolotti F, Tomatis R.

Bioorg Med Chem. 2001 Apr;9(4):939-45.

PMID:
11354677
28.
29.

Synthesis and activity of new acylated diaminohydroxyalkanes as human immunodeficiency virus protease inhibitors.

Marastoni M, Bazzaro M, Bortolotti F, Tomatis R.

Arzneimittelforschung. 2000 Jun;50(6):564-8.

PMID:
10918952
30.

Design of dimeric peptides obtained from a subdominant Epstein-Barr virus LMP2-derived epitope.

Marastoni M, Bazzaro M, Gavioli R, Micheletti F, Traniello S, Tomatis R.

Eur J Med Chem. 2000 Jun;35(6):593-8.

PMID:
10906411
31.
32.

The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.

Micheletti F, Bazzaro M, Canella A, Marastoni M, Traniello S, Gavioli R.

Immunology. 1999 Mar;96(3):411-5.

Supplemental Content

Loading ...
Support Center